2008
DOI: 10.1016/j.jss.2007.08.031
|View full text |Cite
|
Sign up to set email alerts
|

Modulation of Graft Arteriosclerosis in a Rat Carotid Transplantation Model

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
4
1

Year Published

2008
2008
2014
2014

Publication Types

Select...
5
3

Relationship

1
7

Authors

Journals

citations
Cited by 9 publications
(5 citation statements)
references
References 34 publications
0
4
1
Order By: Relevance
“…Our findings, however, do not concur with other studies reporting engraftment of MHC class I − cells in xenogeneic or allogeneic recipients without active suppression of NK cell activity [28][32], [56]. In view of the different strategies used in these studies (i.e.…”
Section: Discussioncontrasting
confidence: 99%
See 1 more Smart Citation
“…Our findings, however, do not concur with other studies reporting engraftment of MHC class I − cells in xenogeneic or allogeneic recipients without active suppression of NK cell activity [28][32], [56]. In view of the different strategies used in these studies (i.e.…”
Section: Discussioncontrasting
confidence: 99%
“…Along the same line, adipose tissue-derived hMSCs that had lost MHC class I surface expression during long-term culture, effectively contributed to skeletal muscle repair in immunocompetent dystrophic mice [31]. Recently, Zdoroveac and co-workers [32] demonstrated reduced immune responses to carotid allografts genetically modified to decrease surface levels of MHC class I antigens through an endoplasmic reticulum-targeted MHC class I-specific intrabody.…”
Section: Introductionmentioning
confidence: 99%
“…Since intrabody was successfully captured in the lumen of the ER by KDEL ER-retention signal sequence, it is possible that the intrabody binds to CD147 and retains these molecules in the membrane of the ER compartment and subsequently diminishes CD147 expression on the cell surface. In other studies, targeting of intrabodies to the ER has been successfully applied to knockdown major histocompatibility complex I (MHC-I) expression (Mhashilkar et al, 2002;Beyer et al, 2004;Zdoroveac et al, 2008) and inactivate various neoplastic cell-surface receptors (Wheeler et al, 2003;Jendreyko et al, 2005;Peng et al, 2007). Additionally, the same strategy was used to block cell surface expression of the CCR5 receptor which is important for cell entry of HIV-1 (Steinberger et al, 2000).…”
Section: Article In Pressmentioning
confidence: 99%
“…Second, recipient APCs present donor MHC and minor antigens from the allograft to recipient T cells. This requires recognition of the allogens as peptides bound to recipient MHC II molecules [39,40] .…”
Section: Discussionmentioning
confidence: 99%